Comparison · NCT03239145-be27d343
[Dose Escalation Dose Level I] Pembrolizumab + Trebananib vs [Dose Escalation Dose Level II] Pembrolizumab + Trebananib: Number of Participants Experienced Dose Limit Toxicities (DLT)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. [Dose Escalation Dose Level I] Pembrolizumab + Trebananib vs [Dose Escalation Dose Level II] Pembrolizumab + Trebananib: Number of Participants Experienced Dose Limit Toxicities (DLT). Trial comparisons, record NCT03239145-be27d343. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03239145-be27d343
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.0000000000000000555 | 0.561 | wilson | |
| Risk in group 2 | 0 | 0.0000000000000000555 | 0.561 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.561 | 0.561 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg weekly.~Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells~Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen | 0 | 3 | OG000 |
| Group 2 | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.~Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells~Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen | 0 | 3 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Experienced Dose Limit Toxicities (DLT)
- Description
- A standard 3+3 dose-escalation design was used during dose escalation period. DLT was defined in protocol section 5.5.
- Time frame
- 3 weeks
- Population
- DLTs will be monitored and collected for treated participants that enrolled during the dose escalation period.
Source ClinicalTrials.gov
Trial
- Title
- Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
- NCT number
- NCT03239145
- Phases
- PHASE1
- Conditions
- Advanced Solid Tumor
- Interventions
- Pembrolizumab, Trebananib
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2026-03-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03239145?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03239145-be27d343